Over the past decade, chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for children with B-cell acute lymphoblastic leukemia (ALL). But unfortunately, CAR T-cells have been far less effective for another blood cancer: acute myeloid leukemia (AML).